Axsome Therapeutics is a biopharmaceutical company developing therapies for the management of central nervous system (CNS) conditions that have limited treatment options. Co.'s primary CNS portfolio includes: AXS-05, which is an oral, investigational N-methyl-D-aspartate receptor antagonist with multimodal activity under development for the treatment of CNS disorders; AXS-07, which is an oral, multi-mechanistic, investigational medicine under development for the acute treatment of migraine; AXS-12, which is an oral, investigational medicine in development for the treatment of narcolepsy; and AXS-14, which is an oral, investigational medicine in development for the treatment of fibromyalgia. The AXSM YTD return is shown above.
The YTD Return on the AXSM YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AXSM YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AXSM YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|